摘要
人表皮生长因子受体2是非小细胞肺癌的驱动基因之一,与不良预后相关。在酪氨酸激酶抑制剂中,波奇替尼和吡咯替尼对该病效果佳;莫博替尼对外显子20插入突变的亲和力高,联合曲妥珠单抗的治疗可用于一线进展的患者。抗体偶联药物的效果是最鼓舞人心的,曲妥珠单抗-德鲁替康更是得到了前所未有的效果。虽然免疫检查点抑制剂不被推荐,但免疫联合治疗或许会为患者带来新的生机。
Human epidermal growth factor receptor 2 is one of the driver genes for non-small cell lung cancer and is associated with poor prognosis.Among tyrosine kinase inhibitors,Poziotinib and Pyrotinib have good efficacy;Mobotinib has a high affinity for exon 20 insertion mutations.Treatment with Trastuzumab can be used in patients with first-line progression.The efficacy of antibody drug conjugates is the most encouraging,and Trastuzumab-Deruxtecan has obtained unprecedented efficacy data.Although immune checkpoint inhibitors are not recommended,combination immunotherapy may bring new life to patients.
作者
张梦珂
曹京燕
周书含
孙清玙
ZHANG Mengke;CAO Jingyan;ZHOU Shuhan;SUN Qingyu(Ward Three,Department of Respiratory Medicine,Affiliated Cancer Hospital of Harbin Medical University,Heilongjiang Province,Harbin 150000,China)
出处
《中国医药导报》
CAS
2023年第17期36-40,共5页
China Medical Herald
基金
国家自然科学基金资助项目(81101758)
黑龙江省自然科学基金项目(H2016047)。
关键词
非小细胞肺癌
人表皮生长因子受体2
靶向治疗
抗体偶联药物
Non-small cell lung cancer
Human epidermal growth factor receptor 2
Targeted therapy
Antibody drug conjugates
